Skip to content

Secondary development of Lingnan validated prescription "Luo" based on human usage experience.

Secondary development of Lingnan validated prescription "Luo" based on human usage experience.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2026001165
Enrollment
Unknown
Registered
2026-05-07
Start date
2025-07-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Interventions

drospirenone group:Dienogest tablets, 1 tablet per day, for a 3-month course.
Leonurus japonicus menstruation-regulating and blood-stasis-resolving formula group:Take Yimu Tongjing Huayu Oral Liquid, 30 mL per dose, three times daily, for a 3-month course.
Leonurus japonicus menstrual regulation and stasis-resolving granule formulation group:Take Yimu Tongjing Huayu Granules orally, 1 dose per administration, twice daily, for a 3-month course of treatme

Sponsors

Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for ovarian endometriosis; 2. Endometriosis staging is ASRM staging II to III; 3. Meet the diagnostic criteria for qi stagnation and blood stasis syndrome in traditional Chinese medicine; 4. Aged between 18 and 45 years with regular menstrual cycles; 5. Voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Pregnant or lactating women, or those planning pregnancy within the next 6 months. 2.Individuals with known allergies or adverse reactions to the components of this medication. 3.Patients with concurrent gynecological conditions such as adenomyosis, uterine fibroids, pelvic inflammatory masses, or pelvic malignant tumors. 4.Individuals who have taken Western medicine or Chinese medicine with similar functions for the treatment of endometriosis within the past 3 months, such as dydrogesterone, gestrinone, Shao Fu Zhu Yu granules, or Gui Zhi Fu Ling capsules. 5.Patients with concurrent cardiovascular, hepatic, renal, endocrine, hematological system diseases, malignant tumors, or neurological or psychiatric disorders. 6.Individuals who refuse to sign the informed consent.

Design outcomes

Primary

MeasureTime frame
Visual Analog Scale (VAS);Anti-Müllerian Hormone (AMH);Sex Hormone Panel;TCM syndrome score;Recurrence rate;

Secondary

MeasureTime frame
Carbohydrate Antigen 125;Short Form McGill Pain Questionnaire;Endometriosis-specific quality of life assessment;Pregnancy rate;

Countries

China

Contacts

Public ContactZeng Cheng

Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital

1090405465@qq.com18538008615

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026